| Lactate dehydrogenase B and pyruvate oxidation pathway associated with carfilzomib-related cardiotoxicity in multiple myeloma patients: Result of a multi-omics integrative analysis M Tantawy, LM Chekka, Y Huang, TJ Garrett, S Singh, CP Shah, ... Frontiers in Cardiovascular Medicine 8, 645122, 2021 | 11 | 2021 |
| Evaluating the utility of proteomics for the identification of circulating pharmacodynamic biomarkers of IFNβ‐1a biologics PL Hyland, LMS Chekka, DP Samarth, BA Rosenzweig, E Decker, ... Clinical Pharmacology & Therapeutics 113 (1), 98-107, 2023 | 9 | 2023 |
| Comparison of data normalization strategies for array-based microRNA profiling experiments and identification and validation of circulating microRNAs as endogenous controls in … LMS Chekka, T Langaee, JA Johnson Frontiers in Genetics 13, 836636, 2022 | 8 | 2022 |
| Race-specific comparisons of antihypertensive and metabolic effects of hydrochlorothiazide and chlorthalidone LMS Chekka, AB Chapman, JG Gums, RM Cooper-DeHoff, JA Johnson The American journal of medicine 134 (7), 918-925. e2, 2021 | 7 | 2021 |
| Circulating microRNA biomarkers of thiazide response in hypertension LMS Chekka, M Tantawy, T Langaee, D Wang, R Renne, AB Chapman, ... Journal of the American Heart Association 13 (4), e032433, 2024 | 2 | 2024 |
| Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients LMS Chekka, RM Cooper‐DeHoff, JG Gums, AB Chapman, JA Johnson Clinical and Translational Science 15 (12), 2858-2867, 2022 | 2 | 2022 |
| Genetic contributors of efficacy and adverse metabolic effects of chlorthalidone in African Americans from the genetics of hypertension associated treatments (Genhat) study ND Armstrong, V Srinivasasainagendra, LMS Chekka, NHK Nguyen, ... Genes 13 (7), 1260, 2022 | 2 | 2022 |
| Lactate Dehydrogenase B and Pyruvate Oxidation Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: A Multi-omics Study M Tantawy, LM Chekka, T Garrett, S Singh, C Shah, MG Fradley, ... Circulation 142 (Suppl_3), A15012-A15012, 2020 | 1 | 2020 |
| PHARMACOGENOMIC GENOME-WIDE META-ANALYSIS TO IDENTIFY VARIANTS ASSOCIATED WITH THIAZIDE AND THIAZIDE-LIKE DIURETIC INDUCED GLUCOSE CHANGE. N Nahid, Y Gong, N Nguyen, L Chekka, E Boerwinkle, A Chapman, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S64-S64, 2022 | | 2022 |
| NOVEL GENOMIC MARKERS OF BLOOD PRESSURE RESPONSE TO THIAZIDE DIURETICS IN HYPERTENSIVE AFRICAN AMERICANS: FINDINGS USING THE LATEST TOPMED IMPUTATION PANEL. L Chekka, Y Gong, N Nguyen, N Nahid, E Boerwinkle, A Chapman, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S71-S72, 2022 | | 2022 |
| VALIDATION OF CIRCULATING MICRORNA BIOMARKERS OF BLOOD PRESSURE RESPONSE TO THIAZIDE DIURETICS. L Chekka, M Tantawy, T Langaee, D Wang, R Rolf, A Chapman, J Gums, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S13-S14, 2022 | | 2022 |
| Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study … ND Armstrong, V Srinivasasainagendra, LMS Chekka, NHK Nguyen, ... s Note: MDPI stays neu-tral with regard to jurisdictional claims in …, 2022 | | 2022 |
| Plasma Microrna Profiling Reveals Potential Biomarkers of Thiazide Response LMS Chekka, TY Langaee, D Wang, R Rolf, AB Chapman, J Gums, ... Circulation 142 (Suppl_3), A15986-A15986, 2020 | | 2020 |
| Differential expressions of miR-17 and complement factor D in carfilzomib-related cardiotoxicity in multiple myeloma patients: Results of microRNA array and proteomics … M Tantawy, LM Chekka, T Langaee, TJ Garrett, M Fradley, RF Cornell, ... Cancer Research 80 (16_Supplement), 3694-3694, 2020 | | 2020 |
| PAIRED COMPARISON OF ANTIHYPERTENSIVE AND METABOLIC EFFECTS OF HYDROCHLOROTHIAZIDE AND CHLORTHALIDONE. L Chekka, A Chapman, J Gums, S Turner, R Cooper-DeHoff, J Johnson CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S41-S41, 2020 | | 2020 |
| RACE-SPECIFIC COMPARATIVE EFFICACY AND SAFETY OF THIAZIDE-TYPE (TT) AND THIAZIDE-LIKE (TL) DIURETICS: RESULTS FROM PEAR AND PEAR-2 PROSPECTIVE CLINICAL TRIALS. L Chekka, A Chapman, J Gums, S Turner, R Cooper-DeHoff, J Johnson CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S42-S42, 2020 | | 2020 |
| SYSTEMATIC, HYPOTHESIS-DRIVEN APPROACH TO IDENTIFY CIRCULATING MICRORNAS THAT PREDICT BLOOD PRESSURE RESPONSE TO ANTIHYPERTENSIVE DRUGS. LMS Chekka, S Singh, TY Langaee, AB Chapman, JG Gums, ST Turner, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 105, S89-S89, 2019 | | 2019 |
